<SEC-DOCUMENT>0001193125-23-060090.txt : 20230303
<SEC-HEADER>0001193125-23-060090.hdr.sgml : 20230303
<ACCEPTANCE-DATETIME>20230303163106
ACCESSION NUMBER:		0001193125-23-060090
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230303
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230303
DATE AS OF CHANGE:		20230303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		23704621

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d449434d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pstv="http://www.plustherapeutics.com/20230303" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2023-03-03_to_2023-03-03">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-03-03_to_2023-03-03">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-03-03_to_2023-03-03">0001095981</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_CurrentFiscalYearEndDate_duration_2023-03-03_to_2023-03-03" name="dei:CurrentFiscalYearEndDate" contextRef="duration_2023-03-03_to_2023-03-03">--12-31</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="pstv-20230303.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-03-03_to_2023-03-03"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-03-03</xbrli:startDate> <xbrli:endDate>2023-03-03</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, DC 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-03-03_to_2023-03-03">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-03-03_to_2023-03-03" format="ixt:datemonthdayyearen">March 3, 2023</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-03-03_to_2023-03-03">PLUS THERAPEUTICS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-03-03_to_2023-03-03" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-03-03_to_2023-03-03">001-34375</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-03-03_to_2023-03-03">33-0827593</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-03-03_to_2023-03-03">4200 Marathon Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-03-03_to_2023-03-03">Suite 200</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-03-03_to_2023-03-03">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-03-03_to_2023-03-03" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-03-03_to_2023-03-03">78756</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-03-03_to_2023-03-03">(737)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-03-03_to_2023-03-03">255-7194</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-03-03_to_2023-03-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-03-03_to_2023-03-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-03-03_to_2023-03-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-03-03_to_2023-03-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-03-03_to_2023-03-03">Common Stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-03-03_to_2023-03-03">PSTV</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-03-03_to_2023-03-03" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;1.01 Entry Into a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;3, 2023, Plus Therapeutics, Inc. (the &#8220;Company&#8221;) entered into a Subscription and Investment Representation Agreement (the &#8220;Subscription Agreement&#8221;) with Richard J. Hawkins, its Chairman of the board of directors of the Company, who is an accredited investor (the &#8220;Purchaser&#8221;), pursuant to which the Company agreed to issue and sell one (1)&#160;share of the Company&#8217;s Series&#160;F Preferred Stock, par value $0.001 per share (the &#8220;Preferred Stock&#8221;), to the Purchaser for $1,000 in cash. The sale closed on March&#160;3, 2023. Additional information regarding the rights, preferences, privileges and restrictions applicable to the Preferred Stock is set forth under Item 5.03 of this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Subscription Agreement contains customary representations and warranties and certain indemnification rights and obligations of the parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Subscription Agreement does not purport to be complete and is subject to, and qualified in its entirety by, such document, which is filed as Exhibit&#160;10.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;3.02. Unregistered Sales of Equity Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The disclosure required by this Item is included in Item 1.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. Based in part upon the representations of the Purchaser in the Subscription Agreement, the offering and sale of the Preferred Stock was exempt from registration under Rule 506 of Regulation D under Section&#160;4(a)(2) of the Securities Act of 1933, as amended. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;3.03. Material Modifications to Rights of Security Holders. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The disclosure required by this Item is included in Item 5.03 of this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;3, 2023, the Company filed a certificate of designation (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Preferred Stock. The Certificate of Designation provides that the Preferred Stock will have 50,000,000 votes per share of Preferred Stock and will vote together with the Company&#8217;s common stock, $0.001 par value (the &#8220;Common Stock&#8221;) as a single class exclusively with respect to any proposal to amend the Company&#8217;s Amended and Restated Certificate of Incorporation (as may be amended and/or restated from time to time, the &#8220;Amended Certificate&#8221;) to effect a reverse stock split of the Common Stock ( &#8220;Reverse Stock Split&#8221;). The Preferred Stock will be voted, without action by the holder, on any such proposal in the same proportion as shares of Common Stock are voted on such proposal. The Preferred Stock otherwise has no voting rights except as otherwise required by the General Corporation Law of the State of Delaware. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Preferred Stock will not be entitled to receive dividends of any kind. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outstanding share of Preferred Stock shall be redeemed in whole, but not in part, at any time: (i)&#160;if such redemption is approved by the board of directors in its sole discretion or (ii)&#160;automatically and effective upon the approval by the Company&#8217;s stockholders of a Reverse Stock Split. Upon such redemption, the holder of the Preferred Stock will receive consideration of $1,000 in cash. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Certificate of Designation does not purport to be complete and is subject to, and qualified in its entirety by reference to the Certificate of Designation, a copy of which is attached hereto as Exhibit&#160;3.1 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01. Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d449434dex31.htm">Certificate of Designation of Series F Preferred Stock, dated March&#160;3, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d449434dex101.htm">Subscription and Investment Representation Agreement, dated March&#160;3, 2023, by and between Plus Therapeutics, Inc. and the purchaser signatory thereto. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: March&#160;3, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">PLUS THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc H. Hedrick, M.D.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap">Name: &#160;&#160;&#160;&#160;Marc H. Hedrick, M.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap">Title: &#160;&#160;&#160;&#160;&#160;&#160;President and Chief Executive Office</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d449434dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES F PREFERRED
STOCK </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pursuant to Section&nbsp;151 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Plus Therapeutics, Inc., a Delaware corporation (the &#147;<B>Corporation</B>&#148;), that the following
resolution was duly adopted by the board of directors of the Corporation (the &#147;<B>Board of Directors</B>&#148;), in accordance with the provisions of Section&nbsp;151 of the General Corporation Law of the State of Delaware, as amended (the
&#147;<B>DGCL</B>&#148;), on March&nbsp;3, 2023, which resolution provides for the creation of a series of the Corporation&#146;s Preferred Stock, par value $0.001 per share, which is designated as &#147;Series F Preferred Stock,&#148; with the
rights, preferences, privileges and restrictions set forth therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Amended and Restated Certificate of Incorporation of the
Corporation (as amended, the &#147;<B>Certificate of Incorporation</B>&#148;), provides for a class of capital stock of the Corporation known as Preferred Stock, consisting of 5,000,000 authorized shares, par value $0.001 per share (the
&#147;<B>Preferred Stock</B>&#148;), issuable from time to time in one or more series, and further provides that the Board of Directors is expressly authorized to fix the number of shares of any series of Preferred Stock, to determine the
designation of any such shares, and to determine the rights (including but not limited to voting rights), preferences, privileges and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, BE IT RESOLVED</B>, that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i)&nbsp;a
series of Preferred Stock be, and hereby is, authorized by the Board of Directors, (ii)&nbsp;the Board of Directors hereby authorizes the issuance of one share of Series F Preferred Stock and (iii)&nbsp;the Board of Directors hereby fixes the
rights, preferences, privileges and restrictions of such share of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to all series of the Preferred Stock, as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMS OF PREFERRED STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
</B><B><U>Designation, Amount and Par Value</U></B><B>.</B> The series of Preferred Stock created hereby shall be designated as Series F Preferred Stock (the &#147;<B>Series F Preferred Stock</B>&#148;), and the number of shares so designated shall
be one. The share of Series F Preferred Stock shall have a par value of $0.001 per share and will be uncertificated and represented in book entry form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. </B><B><U>Dividends</U></B><B>.</B> The holder of Series F Preferred Stock, as such, shall not be entitled to receive dividends of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. </B><B><U>Voting Rights</U></B><B>. </B>Except as otherwise provided by the Certificate of Incorporation or required by law, the holder of the share of
Series F Preferred Stock shall have the following voting rights: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>3.1 </B>Except as otherwise provided herein, the outstanding share of
Series F Preferred Stock shall have 50,000,000 votes. The outstanding share of Series F Preferred Stock shall vote together with the outstanding shares of common stock, par value $0.001 per share (the &#147;<B>Common Stock</B>&#148;), of the
Corporation as a single class exclusively with respect to the Reverse Stock Split (as defined below) and shall not be entitled to vote on any other matter except to the extent required under the DGCL. As used herein, the term &#147;<B>Reverse Stock
Split</B>&#148; means the first proposal to the Corporation&#146;s stockholders after the date of this Certificate of Designation of Series F Preferred Stock to adopt an amendment to the Certificate of Incorporation to reclassify the outstanding
shares of Common Stock into a smaller number of shares of Common Stock at a ratio specified in or determined in accordance with the terms of such amendment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>3.2 </B>The share of Series F Preferred Stock shall be voted, without action by the holder, on the Reverse Stock Split in the same
proportion as shares of Common Stock are voted (excluding any shares of Common Stock that are not voted) on the Reverse Stock Split (and, for purposes of clarity, such voting rights shall not apply on any other resolution presented to the
stockholders of the Corporation). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>4. Rank; Liquidation and Other</U></B><B>. </B>The Series F Preferred Stock shall have no rights as to
any distribution of assets of the Corporation for any reason, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Corporation, whether voluntarily or involuntarily. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>5. Transfer</U></B><B>. </B>The Series F Preferred Stock may not be Transferred at any time prior to stockholder approval of the Reverse Stock Split
without the prior written consent of the Board of Directors. &#147;<B>Transferred</B>&#148; means, directly or indirectly, whether by merger, consolidation, share exchange, division, or otherwise, the sale, transfer, gift, pledge, encumbrance,
assignment or other disposition of the share of Series F Preferred Stock (or any right, title or interest thereto or therein) or any agreement, arrangement or understanding (whether or not in writing) to take any of the foregoing actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. <U>Redemption</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>6.1 </B>The
outstanding share of Series F Preferred Stock shall be redeemed in whole, but not in part, at any time: (i)&nbsp;if such redemption is approved by the Board of Directors in its sole discretion, automatically and effective on such time and date
specified by the Board of Directors in its sole discretion, or (ii)&nbsp;automatically and effective upon the approval by the Corporation&#146;s stockholders of an amendment to the Certificate of Incorporation to implement the Reverse Stock Split
(any such redemption pursuant to this Section&nbsp;6.1, the &#147;<B>Redemption</B>&#148;). As used herein, the &#147;<B>Redemption Time</B>&#148; shall mean the effective time of the Redemption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>6.2 </B>The share of Series F Preferred Stock redeemed in the Redemption pursuant to this Section&nbsp;6 shall be redeemed in consideration
for the right to receive an amount equal to $1,000 in cash (the &#147;<B>Redemption Price</B>&#148;) for the share of Series F Preferred Stock that is owned of record as of immediately prior to the applicable Redemption Time and redeemed pursuant to
the Redemption, payable upon the applicable Redemption Time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>6.3 </B>From and after the time at which the share of Series F Preferred
Stock is called for Redemption (whether automatically or otherwise) in accordance with Section&nbsp;6.1, such share of Series F Preferred Stock shall cease to be outstanding, and the only right of the former holder of such share of Series F
Preferred Stock, as such, will be to receive the applicable Redemption Price. The share of Series F Preferred Stock Redeemed by the Corporation pursuant to this Certificate of Designation shall be automatically retired and restored to the status of
an authorized but unissued share of Preferred Stock, upon such Redemption. Notice of a meeting of the Corporation&#146;s stockholders for the submission to such stockholders of any proposal to approve the Reverse Stock Split shall constitute notice
of the Redemption of shares of Series F Preferred Stock and result in the automatic Redemption of the share of Series F Preferred Stock at the Redemption Time pursuant to Section&nbsp;6.1 hereof. In connection with the filing of this Certificate of
Designation, the Corporation has set apart funds for payment for the Redemption of the share of Series F Preferred Stock and shall continue to keep such funds apart for such payment through the payment of the purchase price for the Redemption of
such share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. </B><B><U>Severability</U></B><B>.</B> Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and
valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise
adversely affecting the remaining provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Plus Therapeutics, Inc. has caused this Certificate of Designation of
Series F Preferred Stock to be duly executed by the undersigned duly authorized officer as of this 3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> day of March, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc. H. Hedrick, MD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc. H. Hedrick, MD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President&nbsp;&amp; Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d449434dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plus Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Series F Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AGREEMENT, dated as of March&nbsp;3, 2023, is by and between Plus Therapeutics, Inc., a Delaware corporation (the
&#147;<B>Company</B>&#148;), and the undersigned subscriber (the &#147;<B>Subscriber</B>&#148;). In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Agreement of Sale; Closing</U>. The Company agrees to sell to Subscriber, and Subscriber agrees to purchase from the Company, one
(1)&nbsp;share of the Company&#146;s Series F Preferred Stock, par value $0.001 per share (the &#147;<B>Securities</B>&#148;), which Securities shall have the rights, preferences, privileges and restrictions set forth in the Certificate of
Designation attached hereto as <U>Exhibit A</U> (the &#147;<B>Certificate of Designation</B>&#148;) in reliance upon the exemption from securities registration afforded by Rule 506 of Regulation D as promulgated by the U.S. Securities and Exchange
Commission under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;). Subscriber hereby acknowledges and agrees to the entire terms of the Certificate of Designation, including, without limitation, the voting rights in
Section&nbsp;3, the restrictions on transfer of the Securities in Section&nbsp;5 and the redemption of the Securities pursuant to Section&nbsp;6 of the Certificate of Designation. The purchase price will be paid by the Subscriber to the Company in
cash at the price of $1,000 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Representations and Warranties of the Company</U>. In consideration of the Subscriber&#146;s
offer to purchase the Securities, the Company hereby represents and warrants to the Subscriber as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">a. <U>Authority</U>. The
Company has been duly incorporated and is validly existing under the laws of Delaware, with full power and authority to conduct its business as it is currently being conducted and to own its assets; and has secured any authorizations, approvals,
permits and orders required by law for the conduct by the Company of its business as it is currently being conducted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">b. <U>Due
Authorization</U>. The Securities have been duly authorized and, when issued, delivered and paid for in the manner set forth in this Subscription Agreement, will be validly issued, fully paid and nonassessable, and will conform in all material
respects to the description thereof set forth in Certificate of Designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of Subscriber</U>. In
consideration of the Company&#146;s offer to sell the Securities, and in addition to the purchase price to be paid, Subscriber hereby covenants, represents and warrants to the Company as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">a. <U>Information About the Company</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">i. Subscriber is aware that the Company has limited revenue, is not profitable and that its financial projections and future are purely
speculative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">ii. Subscriber has had an opportunity to ask questions of, and receive answers from, the Company concerning the business,
management, and financial and compliance affairs of the Company and the terms and conditions of the purchase of the Securities contemplated hereby. Subscriber has had an opportunity to obtain, and has received, any additional information deemed
necessary by the Subscriber to verify such information in order to form a decision concerning an investment in the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">iii.
Subscriber has been advised to seek legal counsel and financial and tax advice concerning Subscriber&#146;s investment in the Company hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">b. <U>Restrictions on Transfer</U>. Subscriber covenants, represents and warrants that the Securities are being purchased for
Subscriber&#146;s own personal account and for Subscriber&#146;s individual investment and without the intention of reselling or redistributing the same, that Subscriber has made no agreement with others regarding any of such Securities, and that
Subscriber&#146;s financial condition is such that it is not likely that it will be necessary to dispose of any of the Securities in the foreseeable future. Moreover, Subscriber acknowledges that any of the aforementioned actions will require the
prior written consent of the Company&#146;s board of directors pursuant to the Certificate of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Designation. Subscriber is aware that, in the view of the Securities and Exchange Commission, a purchase of the Securities with an intent to resell by reason of any foreseeable specific
contingency or anticipated change in market values, or any change in the condition of the Company, or in connection with a contemplated liquidation or settlement of any loan obtained by Subscriber for the acquisition of the Securities and for which
the Securities were pledged as security, would represent an intent inconsistent with the covenants, warranties and representations set forth above. Subscriber understands that the Securities have not been registered under the Securities Act, or any
state or foreign securities laws in reliance on exemptions from registration under these laws, and that, accordingly, the Securities may not be resold by the undersigned (i)&nbsp;unless they are registered under both the Securities Act and
applicable state or foreign securities laws or are sold in transactions which are exempt from such registration, and (ii)&nbsp;except in compliance with Section&nbsp;5 of the Certificate of Designation, which requires the prior written consent of
the Company&#146;s board of directors. Subscriber therefore agrees not to sell, assign, transfer or otherwise dispose of the Securities (i)&nbsp;unless a registration statement relating thereto has been duly filed and become effective under the
Securities Act and applicable state or foreign securities laws, or unless in the opinion of counsel satisfactory to the Company no such registration is required under the circumstances, and (ii)&nbsp;except in compliance with Section&nbsp;5 of the
Certificate of Designation. There is not currently, and it is unlikely that in the future there will exist, a public market for the Securities; and accordingly, for the above and other reasons, Subscriber may not be able to liquidate an investment
in the Securities for an indefinite period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">c. <U>High Degree of Economic Risk</U>. Subscriber realizes that an investment in the
Securities involves a high degree of economic risk to the Subscriber, including the risks of receiving no return on the investment and/or of losing Subscriber&#146;s entire investment in the Company. Subscriber is able to bear the economic risk of
investment in the Securities, including the total loss of such investment. The Company can make no assurance regarding its future financial performance or as to the future profitability of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">d. <U>General Solicitations</U>. Subscriber is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the knowledge of Subscriber, any other general solicitation or general
advertisement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">e. <U>No Rule 506 Disqualifying Activities</U>. Subscriber has not taken any of the actions set forth in, and is not
subject to, the disqualification provisions of Rule 506(d)(1) of Regulation D promulgated under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">f.
<U>Suitability</U>. Subscriber has such knowledge and experience in financial, legal and business matters that Subscriber is capable of evaluating the merits and risks of an investment in the Securities. Subscriber has obtained, to the extent deemed
necessary, Subscriber&#146;s own personal professional advice with respect to the risks inherent in, and the suitability of, an investment in the Securities in light of Subscriber&#146;s financial condition and investment needs. Subscriber believes
that the investment in the Securities is suitable for Subscriber based upon Subscriber&#146;s investment objectives and financial needs, and Subscriber has adequate means for providing for Subscriber&#146;s current financial needs and personal
contingencies and has no need for liquidity of investment with respect to the Securities. Subscriber understands that no federal or state agency has made any finding or determination as to the fairness for investment, nor any recommendation or
endorsement, of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">g. <U>Tax Liability</U>. Subscriber has reviewed with Subscriber&#146;s own tax advisors the federal,
state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement, and has and will rely solely on such advisors and not on any statements or representations of the Company or any of its agents,
representatives, employees or affiliates or subsidiaries. Subscriber understands that Subscriber (and not the Company) shall be responsible for Subscriber&#146;s own tax liability that may arise as a result of this investment or the transactions
contemplated by this Agreement. Under penalties of perjury, Subscriber certifies that Subscriber is not subject to <FONT STYLE="white-space:nowrap">back-up</FONT> withholding either because Subscriber has not been notified that Subscriber is subject
to <FONT STYLE="white-space:nowrap">back-up</FONT> withholding as a result of a failure to report all interest and dividends, or because the Internal Revenue Service has notified Subscriber that Subscriber is no longer subject to <FONT
STYLE="white-space:nowrap">back-up</FONT> withholding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">h. <U>Residence</U>. Subscriber&#146;s present principal residence or business
address, and the location where the securities are being purchased, is located in the State of Texas. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. <U>Limitation Regarding Representations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">i. Except as set forth in this Agreement, no covenants, representations or warranties have been made to Subscriber by the Company or any
agent, representative, employee, director or affiliate or subsidiary of the Company and in entering into this transaction, Subscriber is not relying on any information, other than that contained herein and the results of independent investigation by
Subscriber without any influence by Company or those acting on Company&#146;s behalf. Subscriber agrees it is not relying on any oral or written information not expressly included in this Agreement, including but not limited to the information which
has been provided by the Company, its directors, its officers or any affiliate or subsidiary of any of the foregoing, as investment advice or a recommendation to purchase the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">ii. Subscriber confirms that the Company has not (A)&nbsp;given any guarantee or representation as to the potential success, return, effect or
benefit (either legal, regulatory, tax, financial, accounting or otherwise) of an investment in the Securities or (B)&nbsp;made any representation to Subscriber regarding the legality of an investment in the Securities under applicable legal
investment or similar laws or regulations. In deciding to purchase the Securities, Subscriber is not relying on the advice or recommendations of the Company and the undersigned has made its own independent decision that the investment in the
Securities is suitable and appropriate for the undersigned. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">j. <U>Authority</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. <I><U>Entity</U></I>. If the undersigned is not an individual but an entity, the individual signing on behalf of such entity and the entity
jointly and severally agree and certify that (a)&nbsp;the undersigned was not organized for the specific purpose of acquiring the Securities and (b)&nbsp;this Agreement has been duly authorized by all necessary action(s) on the part of the
undersigned, has been duly executed by an authorized officer, agent or representative of the undersigned, and is a legal, valid and binding obligation of the undersigned enforceable in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. <I><U>Individual</U></I>. If the undersigned is an individual, the undersigned is of legal age. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Legend</U>. Subscriber consents to the notation of the Securities with the following legend reciting restrictions on the transferability
of the Securities: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES
ACT&#148;), AND HAVE NOT BEEN REGISTERED UNDER ANY STATE SECURITIES LAWS. THESE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE OR TRANSFERRED, WITHOUT FIRST OBTAINING (I)&nbsp;AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH SALE OR
TRANSFER LAWFULLY IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT AND UNDER THE APPLICABLE STATE SECURITIES LAWS OR (II)&nbsp;SUCH REGISTRATION. MOREOVER, THESE SECURITIES MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF THE
COMPANY&#146;S CERTIFICATE OF DESIGNATION OF SERIES F PREFERRED STOCK, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Accredited Status</U>. Subscriber covenants, represents and warrants that it qualifies as an &#147;accredited investor&#148; as that term
is defined in Regulation D under the Securities Act. The information provided under this section of the Agreement is required in connection with the exemptions from the Securities Act and state securities laws being relied on by the Company with
respect to the offer and sale of the Securities. The undersigned agrees to furnish any additional information which the Company or its legal counsel deem necessary in order to verify the responses set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Holding Status</U>. Subscriber desires that the Securities be held as set forth on the signature page hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Confidentiality</U>. Subscriber will make no written or other public disclosures regarding the Company and its business, the terms or
existence of the proposed or actual sale of Securities or regarding the parties to the proposed or actual sale of Securities to any individual or organization without the prior written consent of the Company, except as may be required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Notice</U>. Correspondence regarding the Securities should be directed to Subscriber
at the address provided by Subscriber to the Company in writing. Subscriber is a bona fide resident of the State of Texas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>No
Assignment or Revocation; Binding Effect</U>. Neither this Agreement, nor any interest herein, shall be assignable or otherwise transferable, restricted or limited by Subscriber without prior written consent of the Company. Subscriber hereby
acknowledges and agrees that Subscriber is not entitled to cancel, terminate, modify or revoke this Agreement in any way and that the Agreement shall survive the death, incapacity or bankruptcy of Subscriber. The provisions of this Agreement shall
be binding upon and inure to the benefit of the parties hereto, and their respective heirs, legal representatives, successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Indemnification</U>. The Company agrees to indemnify and hold harmless the Subscriber and each current and future officer, director,
employee, agent, representative and shareholder, if any, of the Subscriber from and against any and all costs, loss, damage or liability associated with this Agreement and the issuance and voting of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Modifications</U>. This Agreement may not be changed, modified, released, discharged, abandoned or otherwise amended, in whole or in
part, except by an instrument in writing, signed by the Subscriber and the Company. No delay or failure of the Company in exercising any right under this Agreement will be deemed to constitute a waiver of such right or of any other rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Entire Agreement</U>. This Agreement and the exhibits hereto are the entire agreement between the parties with respect to the subject
matter hereto and thereto. This Agreement, including the exhibits, supersede any previous oral or written communications, representations, understandings or agreements with the Company or with any officers, directors, agents or representatives of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Severability</U>. In the event that any paragraph or provision of this Agreement shall be held to be illegal or
unenforceable in any jurisdiction, such paragraph or provision shall, as to that jurisdiction, be adjusted and reformed, if possible, in order to achieve the intent of the parties hereunder, and if such paragraph or provision cannot be adjusted and
reformed, such paragraph or provision shall, for the purposes of that jurisdiction, be voided and severed from this Agreement, and the entire Agreement shall not fail on account thereof but shall otherwise remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Governing Law</U>. This Agreement shall be governed by, subject to, and construed in accordance with the laws of the State of Delaware
without regard to conflict of law principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Survival of Covenants, Representations and Warranties</U>. Subscriber understands
the meaning and legal consequences of the agreements, covenants, representations and warranties contained herein, and agrees that such agreements, covenants, representations and warranties shall survive and remain in full force and effect after the
execution hereof and payment by Subscriber for the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[</B><B><I>Remainder of page left blank intentionally - signature page
follows</I></B><B>] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For good, valuable and adequate consideration, the receipt and sufficiency of which is
hereby acknowledged, Subscriber hereby agrees that <B><I>by signing this Subscription and Investment Representation Agreement, and upon acceptance hereof by the Company, </I></B>that the terms, provisions, obligations and agreements of this
Agreement shall be binding upon Subscriber, and such terms, provisions, obligations and agreements shall inure to the benefit of and be binding upon Subscriber and its successors and assigns. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INDIVIDUAL(S):</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Richard J. Hawkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name: Richard J. Hawkins</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Number of Shares Purchased: <U>1</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purchase Price Per Share: <U>$1,000</U> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aggregate
Purchase Price: <U>$1,000</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Subscriber desires that the Securities be held as follows (check one): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Individual Ownership</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporation</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Community Property</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trust</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jt.&nbsp;Tenant&nbsp;with&nbsp;Right&nbsp;of&nbsp;Survivorship</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limited Liability Company</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(both parties must sign)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partnership</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenants in Common</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (please describe):</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Company hereby accepts the subscription evidenced by this Subscription and Investment Representation
Agreement: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andrew Sims</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Andrew Sims</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President and Chief Financial Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES F PREFERRED
STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See attached. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pstv-20230303.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/4/2023 2:09:51 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:pstv="http://www.plustherapeutics.com/20230303"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.plustherapeutics.com/20230303"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20230303_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20230303_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pstv-20230303_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/4/2023 2:09:51 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pstv-20230303_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/4/2023 2:09:51 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pstv-20230303.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140509109708800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  03,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLUS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0827593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4200 Marathon Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(737)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-7194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PSTV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d449434d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pstv-20230303.xsd" xlink:type="simple"/>
    <context id="duration_2023-03-03_to_2023-03-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2023-03-03</startDate>
            <endDate>2023-03-03</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2023-03-03_to_2023-03-03"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2023-03-03_to_2023-03-03">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-03-03_to_2023-03-03"
      id="Hidden_dei_EntityCentralIndexKey">0001095981</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="duration_2023-03-03_to_2023-03-03"
      id="Hidden_dei_CurrentFiscalYearEndDate_duration_2023-03-03_to_2023-03-03">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="duration_2023-03-03_to_2023-03-03">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-03-03_to_2023-03-03">2023-03-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-03-03_to_2023-03-03">PLUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-03-03_to_2023-03-03">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-03-03_to_2023-03-03">001-34375</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-03-03_to_2023-03-03">33-0827593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-03-03_to_2023-03-03">4200 Marathon Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-03-03_to_2023-03-03">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-03-03_to_2023-03-03">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-03-03_to_2023-03-03">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-03-03_to_2023-03-03">78756</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-03-03_to_2023-03-03">(737)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-03-03_to_2023-03-03">255-7194</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-03-03_to_2023-03-03">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-03-03_to_2023-03-03">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-03-03_to_2023-03-03">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-03-03_to_2023-03-03">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-03-03_to_2023-03-03">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-03-03_to_2023-03-03">PSTV</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-03-03_to_2023-03-03">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MQ++\=E VM,B*]_65T/#V7QQN&860,S? ];40^M@PGP"J+SB3?P%02P,$%
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ W8-C5B0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ W8-C5@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #=@V-6246N\^T    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    ( -V#8U8<.&7J/P$  #P"   /
M  "  9,0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #=@V-6)!Z;HJT
M  #X 0  &@              @ '_$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " #=@V-699!YDAD!  #/ P  $P
M@ 'D$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   N%
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d449434d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  d449434d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d449434d8k.htm">d449434d8k.htm</File>
    <File>d449434dex101.htm</File>
    <File>d449434dex31.htm</File>
    <File>pstv-20230303.xsd</File>
    <File>pstv-20230303_lab.xml</File>
    <File>pstv-20230303_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d449434d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d449434d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pstv-20230303_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pstv-20230303_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pstv-20230303.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 4
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "pstv",
   "nsuri": "http://www.plustherapeutics.com/20230303",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d449434d8k.htm",
      "contextRef": "duration_2023-03-03_to_2023-03-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d449434d8k.htm",
      "contextRef": "duration_2023-03-03_to_2023-03-03",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.plustherapeutics.com//20230303/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-23-060090-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-060090-xbrl.zip
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MN=X NUN=1'5)\00;,1C28A*>T6&VI79H,!#1OK:-?OIM0?*)[Z!=ZN_& NE
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M[J"B<PE:KYAK,QLW8B2?!(ZB+O,"Z<R)!*V1H[D>(6S@#8%?!NF&&R2)]&<
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M];5KS7(TH^_] ["W\^-CT2?9<!3 _K"7.V<G2+YY.P#>&.U_6$3("=;$H_<
M^P(_ 12V#N$[=0MJ!\6EU ?@%F3,CNP@L*2)20'<-T]N</,HQG9Y1 X0)2Q
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MYR4NACX5)H=OD^@:38R8XC*A6T;995)89C'%[M5Z3!DPN\K8P<>H%Q_'Z$\
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M67E1UWSQ1WE_S<,+,UYM9+<I85?"_?Z1A08JJ%79YS^H]O#4;-(O/[]8[4(
M.@"W/:R*4O;X]&*(IYT&[?/.Q:A[.&R);N]PZRL4-!:?EVN_?8FBQ_[!W>XJ
M;6;5SKU%D>5:[-&UE78<IK")H9X]<U&%$$(5E:?IZY?=P C[QI^X@T]4-7'G
M!U A'DZUFHAC=^%?GYOXFC0_=S&([^T,3^XZ<;_R],5^:W6S*GRAWUJ]XJCK
MRP $0'S[$F+3K\M>.-6+U[7U#__Q'"7$.CQ#O.?"_,;>50?. +3^T6=X2+]T
M_O\!4$L#!!0    ( -V#8U:W!H>3$PX  /PS   0    9#0T.30S-&1E>#,Q
M+FAT;>U;:6\:21K^CL1_*'EV1K&$\9%C9AR"9$,[1DN,!3C9[&H_%'0!)3?=
M;!^VF5^_S_M6]<5E.Q-G]L-&F=A]5+W7\Y[5T[@<?NHV&Y?.6;M9K32&G6'7
M:3K_.'A=/VX<FBO</K3/1>.\U_XJSC^V>MU>_\/>E\O.T-EKBFH%+[64'ZNP
MV6AW/HO!\&O7^;!WK]UX=OI;_:WV]X3T]-3_L.>I2;S'>UVGK\UE.-7^01PL
M3H\6\7MAKT=!' =S<VL2^/%!I/]0I\?Y]43.M;<\'>JYBL25NA?]8"Y!Z:S;
M^7CU82_4TQE(-<Z;SL-,CW0L()5H')XW&X?7)-8F!HY/OB,'8U8)LW#=O1F(
MX:73/[MV;H:=UJ F.E>M^F/LO'L9;EI.?]BYZ+3.AH[H78BV,\ ;9\-.[^HQ
MAKZG@0H,@8F4\,L#HT!WX/0[SD!<B.N^<^'T^TZ[6AD,>ZV_/\+.2]CE.@FC
M1/JQB ,Q4.-8!_XO_BA:O#]^>RR"B8AG2OQ@RWQ4O@JE)UI!N A"22R)KKQ/
MN1G$,E9TT5:>O)?A3OZ^BV<UX4+BYJKM] FQ3ENT>S ?W,HY_RH,JK_6!+@<
MJ9GT)L3;M9=$8CB#' N5Q'H<P?/\<;TF9,[VN"#?*Y+LEY^.W_SZGCPE?T*(
MH/N_O=^O07P9LPXF@><%]]J?5BNAB@(OX4WN923<Q%L*Z0:+6+EBM.2W1X$,
M7>+*U2%,'(11JLO65A;.TS7M=$V)$^T+.88 KO3'2MSK>,;[+<+@3D?8C2EL
MP]-S#0RM14+.E>]")F*S6LGX;']L=4N<8:]/,AS/#-77-7%R=()_[V=Z/!,%
M93&K+NP\"4(F.PZ58064I8A4J-4F/1&A=^\C<1VJB0I#<#2(@_%M32QD*.ZD
MERCQMZ/ZT=&Q6*A01#/FWU#7,(^*D) D&0<R&2D&AM3%VI9&IDR[L#4E%T!I
MP2\JJ)XO])WVU!1;2-\E$>-0L^(C2!&3?&9]J+1?%]O#R_?Q%=CD"[G&V8#,
M4F/UG5G;$7]]\,?RMU08ZXD>6V/#/0IP,'JO5DH S5%@MLW]9<=6)7"4C"[%
MV),1VW@L%SH&(B/2^R;GN/6#>Y],MF;V,?2LHQB^2.O>UHZ.CN@_(9-X%H10
MFFM $.U"R"JJ5ZB472]"P!YY" )A,!<Q]$^QFW_"*P,?*@C%/,"F!L,U5OLD
M"0D"N0:R6++NZ014]0"011$%DUP0T)GH!U[E)_,1ML,R(QU[C;\L^,V:IK#:
M58CP<PT>6=[4&U*OH_4)'"55&#&^NDH8)Q"OM#_V$I?T/DIBX0>Q\/1<QX;-
MNX M8M[=?X;'3$,D0[,'U*CGBR#"5;( A\3>_0R1=RD2GZQ IMTF;OWELQ)P
M<M7[4N,"S[GH]9V:.'=$9RCZSJ#7_>RT4P>4,60NY'EKT7A)X+5,LX1;X&#3
MR"XOJ\$>^R;DRFIEJU:0(8U5*1IA6TU&SO%E":VS0-NG^V]ATNZ8[1;Q5NPL
ME*+P+KF&\3;.39N#+G,'8D^C!F\PA+XA-I/K9&#?Z#"49%U7LWN0V8"_0H+-
M8[OV'[6/<7<B)!<+#^]0 *$]/6\EU:UQ(2-;;D2GNS!]\N9EBN6AT_\TH'XA
M*Y;%4VKE[^9BQW7J1<_IU\9-LYU'K!K26I# H\BRUPCMGRFT-PYOFO;U.OVD
M(G![E#!%A\K\ 5B 049JI4[8"M9RS;;MM5+ZX)BZ*8!'09$J<U*M@!6X3=U(
M\:CO&/9G\@XP*V0[+%E+>,3&O3;")G"6#+JN]11*/XI#,> ]"H);@:MP29"?
M_YC@>F(;96-X36G3=Z.-!D96<(TRMQ9S9$?R]YK5$B4LR ZA=.R9A(/@HC1T
MYZ:TTJ1XJWWWQ\C\NBCS9Y-$^QS9BG+S.\[#6"UB$BN@RN)>1RJM+MRGI S*
MKZ'Z3Z)#\SYJ?5/6Y<J,"ZA#B_P$V)6:HW(5<+JC]-W66=M;-#XZ??/SMZCS
M^'%=F<K<R!XD,<ICG\N:YTG^]B@K/2&VBHS/;MKO,?^EY8#C5''!F/5V:UN9
MRCF8SV'+Z+$>:*W#Y67KX6E3X4]UOXA %SG+E.SJ ;5?!%]!+<8,@IL%4C-7
MPJ#35W<JC)05:X",%W/[X*H)RDC 30$A^QQIMGHCJ\&6?6PUH"%&5B+B9$Q+
M2CW$6)4C.?$)O/2$6M.Z.(M$$JU8F<K97!<E9F%LXC;7B9@KZ9MB9J+#*";<
MH"A%LV(9V-";LC6,&T%UD]@RY%HWC&<H\%=<LUTNQ;="A&H&FBY +:89FRL_
MT\7N"H0#')E/3Y:KB$+-F$&JB T$?Z(HHCFL!#$VM1VE]ZG*$4Q1$"+ C<D@
M"#99&^%N&U_0\[PPR\3;&7I?+G2<<.AX3N8%@@FU:(]))*@74K+N;3@VD. 9
MR38OL;5D!.&K%89:F/K@-HV'EJIXQ6[) 8);N<WO9Y4H^1POW-_%T"L I,;]
M.EH8ZL9,V/$D-3 U8ZE2G"]X--6ZR[(/ER9 :85AX L,%OUF?0JPGP'AL-WY
MC&QH3Q^J%<%_&PMXWM)3Y=2LYFOXH%L+.54'(Y1_MP<C!?'4J?3NY3*B8XK&
M95\,.O\$T%[OI5ORZ<?I3[_SGSWQI=,>7G[8.SXZ^CFKFEO.%:KE_[FC$5M-
MO*F+OO1OWXNN1JAT;6A'!.Z18=;*"\+]4_*>'Z1V!T3CH%HA6[N:&JU1DDT6
M(G1+&Z>>/ C""A@BHIH^GRJ8GE]X.;<U,8( 8;*(QT!>J()P*GW]AWTV5^&4
MG$N.L2#2YB;B-#I>L).A+J"4ZEL*&SBB8:')O'=8XL? .6$X!&>%&S^F&H35
MWJ*.")& )L\UT5PNTZR:;D /R?>A;AY7H3NFV6M0S%?DLRB,D-ZL:C;$A&HE
M#6]FYDR[W",<(!'S.(XRDEV]WKK7\\1;X&LUW];LK#Q5?7J56P<A-;4XT0R\
M#"0F6B,6SJ0_9>N;EKU&6V7U7\W&6<)';!FIB:F>T+ &)0BM5/X8^2ZD)%4#
ML"-*T9QOTXT(68B)NC S?4*R>)5BGOP&U*GD,6(B8*@H-L-B,P&S<^-]8=?(
M::@4\0"@AR$)F#+$A4]6(;Y*]80G! /D%3(1'NUSN)6WRD3EB:W90S4-.'.8
M\<B/ ?@[D+E! >:J^<(,BV^:]6\\A?NS"?^=[16&E(F^I6Z'I^$668<+'!I5
M D/I<!1W4)V3V7(//,VG=MH6/6&F"YH"&V?<-9FC?34E71 C-(X!',:Z3* 9
M>,18TL"4XKR:3.A Z(ZK:B;&48 >466*])L5;,\G!YCE(\)=M+-!9Q9HTE[U
MD3J:>_'GU[QZ#F\V"[9%LU?9X+N@_>+ E@OVTFD:P+)R!E($<=9/;6X_-JP1
MA,A"$#2(HE!HFIQ,?6RR+#2GR_^2"OG=LRKDHFN4F7],U9O=B\]]  PV=+62
MGB)R3"T.<Q@S/"=$AVBZMK\=<YM.F\AHMM(9%_BZ#O6X8)3][*CR<6FYR(8D
MP3VU.W@3[*#=X0G$!)B$$!J(]99Y$K8^D0Z'5[!AIW)6_H+&JI6R-FD(L.0=
MBIZV9===QY$O!YO7#)L+.CXCJ?(&V<2CV![7/J)I=.JF0XT$Q1EHA<Q3$#!+
M@>5P5"P"]C=UHNN.7CXG>"0-C%')\FQ_5.JP\\EOX'LV]Q>R+VJ9PN!M,\%J
M9?M0,YWE%I"_W?0,[*<.E?LIZ-;C]+KG[IAJ9%Y<-@<ED#";.B/BAUE#*.BD
M.HEX!$=N7#BH0E+-SP"W'N"P![ NBZ'R"MVJ.9&2B+ J/3I^2@[* D RFH.Z
M33'&6FNY:ED:%=E4OK7/MN!!5$,]F,3<GH--E"*KP;X\?=EYD(9W$B\;*F2*
M7]GL:2%-QJM\<%Q:;/N B>HIRGK!I(ZL3)+YYG$^[YEH+U/^&GBJE=)ASRKT
M9M(<P4FJJL0DH7$]3RGDDK-]:JIO$C6;2X)KX"-AO[I5:F%L;:A9RJ##-U/"
M\2P,DJG]'L?>LY2A*S0E/'LF!&YD$658YOP_Y&N17XM'#@-"IAS!+O%R[:3E
MRTSY]%P U)$>476K)$F>'HI:>^>NSAW- BYN9W[@%R@(S:B ![Y980.=5RLH
M!W4ZPBV$+CZ:()_7D_(I;$I0TXFPY]I-\9@__30QR[3N.S:&"6R4R/<M2% L
MFQ&ORF/G-%:G).V$P1+D"5G:*]M[TL2;0A)"<',Y'E"M;(CA#2YFU%QJGZX*
MY\ZI3[TP-%:/@O_59V9L@KJ64P6O)AV *0[D710$XMR3_NV__S^FLPJ/ 9,#
M4IK_#;52YPKL#Z^<P4#P%UV]B]JV[QHY&HXE=QJ/GR[L.- R#L0?,:H'-4X*
M7S&:^0*VP2WSE6.>CX,):!F_3H/YZ\;@)E-5+O>O;Z&&.^(.Z?^ E7L*#>XU
M0[=QB!5-]*(\E>"/",W7@^O=34&/A/452ZP98J]I4A)MPX8N?RQ.F!R>G7<=
MT7*ZW<'U6:MS]?'#WM$>7U^?M=OIM873&T+3>:_?=OI\VW)E[AP @MVSZX%S
MFOZRT\ZKH""0&3<9]IOVEW9*^->?$;(/A^W\P6<KBA$V!WSZ8GG][R?I??S3
M+U!*12BXF^;^ZE3>!8B<SQ1AA3DRL( VH-HK<M8=W\:;V4_*8)FY I4"D4NG
M\_%R")'?E44NW,]IG^QMW?WE1&^>+T^+G*W:S#)@$75PWAL.>Y\@XX/@L:;X
MZ8C_Y"A>WXHU7(;A]FT.HT-VK[JXQ%_EHAA!L?RI_1=H9H=:=DB;OO'7"Y%R
M\N?D0!0FCOS8O/J+G"_>B]9,JXEP. I3]=$S,;;HO?A!8:MI$JW8G''A4;WV
M5]SD_^OGOU!+ P04    " #=@V-6C'21!D,#  !C"P  $0   '!S='8M,C R
M,S S,#,N>'-DO59-;]LX$+T7Z'^8ZM0"*]&RFZ(6XA39I@$"I&GAIHN]%;0T
MMHFE2)6DDOC?[Y"2'-F)73=9;'P(S9DW\^:3/OYP5TJX06.%5I,H3081H,IU
M(=1B$M4VYC87(OIP\O+%\:LXAK/SBRN(8>E<93/&;F]ODV(NE-6R=F3!)KDN
M&<1QI__Q^CO\U5C/8(H2N44HN75HX,]:R"(;#H;#-!V\3][U80:YMP<%=YC!
MB+UEI#>"83889T<IG'Z&3\&(@FM18A^IJY41BZ6#U_D;"* SK11*B2LX%XJK
M7' )WSK"?\"%RA,XE1*F'F:)I45S@T726KVS16;S)9;\Y0L 2I>RF2*3=3F)
M?![:--S-C$RT6;#"&>96%3)2BDD+C<BC'O37N <8JH.7V#5PSNTL@#J)3\^P
MAZBLN]EP4\G:NB4:7B$%GC>%\ND9T*<'+%"L<8&:Q3Q9Z!M&@FTG7BX>#V8X
M&(P8]86C?&,/(H7Z9P_"BV?4(GTG#R"WHP!(Q^,Q"](M2H7;C*"U?L0:8=#F
MSADQJQV>:U.>X9S7DE"U^EES*>8"BZ!%_5JB<ALZFQJ.FP6Z*UZBK7B.3THY
M-=AC\1'EE/W]^?);Z+WHQ , 0CN*LM+&0=.5ESH/L[(GK?Y;W%4C]E=Q.HQ'
M:4+&(E"/LM]12F#/)M(5^4E$UAUR,!&[JY/](?:'7=X?[_\G9V![P'W\8Q]_
M^NZ@^!\LB/^ B597SR73VW)/KXGB-"!-5<+Q\+K<(Y_5F]UV\'DXVNMX>YVT
M7H-/KI1VP5&?":\JH>:ZO:)+W\19U\E3G$-88QDWN=$2]R\[5AE=H7&"EO[]
M,#0&E@;GD\CO_KC;,S\DGR6T9SJ5!PXVQ\N+&4%07M[3Z[!.. ^^]&+P<GH]
MN5R;]NTPB2SE7?;&\W\.MS+XN^$2Q-*6#V7;'?77GM9O!^_]7),&^,/WZ<6O
MWXGU0\$<O]-*EZN&[)G.:_\F=?]/5?%)$<75!768*0.]" 2]*%-2_W&0^IIL
M1[= ^DTG0ANG _]'/_DZ"_TC5P4TYJ!G[YAM&]FV7ULLOJB3<,ZYS&NY3GX+
M;C7V ;?+=CCRGMEN7'O;%:X;9[8]S^U-?^Z;JV;OT-=_ 5!+ P04    " #=
M@V-6VV*]*+,&  "E20  %0   '!S='8M,C R,S S,#-?;&%B+GAM;,V<;6_;
M-A#'WQ?H=[AY;S:@LF-G&Q:C:9$YR1 L:8+&W2.&0I88FYA,&J0<V]]^I!X:
M.:9DRCQ5>=%6E>[^=W_G=PXCF7G[?CV/X)$(23D[[?2[1QT@+. A9=/3SE)Z
MO@PH[8",?1;Z$6?DM+,ALO/^W>M7;[_Q/#B_O/H 'LSB>"&'O=YJM>J&#Y1)
M'BUC)2F[ 9_WP//R^-'X$_R>EAO"1Q(17Q*8^S(F GY9TB@<#HX&@W[_Z.?N
M3\4T07RM!Z$?DR$<]W[HJ;AC& R/3H8_]N'L!BX2$09C.B?%3+[8"#J=Q?!=
M\#TD2>><,1)%9 .7E/DLH'X$]WG#;^"*!5TXBR+XJ-.DZE(2\4C";J8:4?;?
M4/\UT;W#ZU< ZD5D,CEWVM$O1?9*K"<BZG(Q5;T>'??RE,Y3QGHG976<)/1/
M3DYZR=5BM*2F6"7>[_UY<WT?S,C<]]2+K[Y8059&TJ%,SE_S('D%+1J$T@C]
M/R\/\_0IKS_PCOO=M0P[[W3![-7Q)R2Z5D>0>!@*'I&*POIR4KV3Q<>;A8HG
MZYBPD&3*7[1YD$7-!'E(535ZB:0D07?*'WLAH1J0@3[P]('N\%OUG\\CKF@_
MF\A8^$&\72_2+Q$7^<G$Q&G'D-3;;DC'G8E@2\L70:ZC#O?XSR)Z 5=?MT7L
M)8IY^H/@<V,763ENN/@YFD3&-C5)ZD@/-V'>I_M]7E.AHC%!)%\*A5>=+VWB
MYUVB#/_DVO^^[3W5?BFMJK<02:[K]NN&Y#T)EH+&FXMU,%-^R0=_3FS)-.>V
M!&BE$5X>XX)KN1X2M7D!R"N +N',;G-]%Q&NV[P;R&=S]7ZM_L27D3^U)?A9
M4DOHFEOGAHLNL!J$D"C]H@Q:VIG.!AHM8FG;K1N.%RQ6Z(]4&>%'5VHEL?Z-
M;&RQ+$EN"<]J*[PBR 77"D$D;-,*D)6 I :H(LX -]AZ$>3Z_3NN7I="Z*FD
M,O"COX@O+EAXKGXDLE[(EN:WM:;=9XA7QSFM="LUL1:]:1%(JX N ZH.Z$+N
M"^!&'6RMA0^RX0;[.0^6^IO$6#FP!7P[IR6HC8WSW6LN\.[J( &;"X-6=B84
MO\TBE9:]XF!X1P3E8<TWW)+DEL$T6^$501BH&@2QF4U+X+W!-MBZD6/K_C%6
MQA_)E.I;&RRN<\?!G-OJNKC$""^/<5\5F_1P%\5/%7#N.#37MV%%;-T\!LA7
M+.!BP45R@_L^5H,SXDNU(M^,>%B3ZSU2K6)N9Y-;I[@/@84\[DQL%82D(F0E
M0==$&I*OX,LP,X>;PQBB2QJ1#\OYA(AZ$U/,:W4\# :X^;H[^,^U<"G7ZI#*
M(P&-W:^!7JNF,4 =^^NK4"V6Z --'VD>0FVI2*L([[/&+8+=X:X4QB5=E8+M
M6KC<-VK%, 0'^,$8B;,P5 9D]L\U9:1?;QR, JV.0I4EOB?0?01*17'QS_3?
MY >@*\$MPUK'-&;#@/X!7II!?^"*_N#%H3^P17_0!/J#KX?^>,4;0Q_)AC7Z
ME5X0T1^IPULQYBMV$/C%])> O<&."?JG,#3DGTLV!+PN UR +H0+.[:!*M3M
M7"!BGOP\?"ON!'^D+*AY6Z=,XR4 7V;,1/VS6#3TC;H-\9_>V%#HY-5PAZ 1
M*U634,,/XCC<<1G[T=]T4?\>IUGA)8R"V91I$+8BT<; H-K0$*250)7"O&_9
MG(VJ ;#VXOC9%VU0$+\.\-LY;7W&Q=0XW[WF]%F6'1TD<)/O\UH9AU/\/K<^
MI6+9K!N(>BM%=#?CK.;]\MV\EH L-<#-UUW -&LAP9F(0Z*.==^PF7Z+D-9I
MV@W4/P2-8\)&?#Y?LNQ^I+2EM22Y)62KK?"*(!=X*P21",XJP'8)9XH;;+R(
M<MWN'??)\(@&-*9L>J-6W(+ZD2W+ILRV]LB4F^!E$4[[8TK4D/A]DH=<WWUK
M3$,M;VV,J=.W&[9W@NCY( J+Y).0>D^CN'UXL%\X5"FTA+&%*;XOT@7K?:I(
M>*LR4*P#:2%(*CF#WK2)(O '.D%%_TK*)1'N V#0>1EC4&[0/ P[\8@C4:+=
MU&"DY1J=CX8<54Y)+5LXVX#[@\F8QE'M+<!/>2UO_]TQP,W7,;;];FMA+6KR
M7;-*'1)YM.V^N/T:M_I:-.T&ZECX^O>#W&_F$VZ]!'^6U!*BYM:YX:(+G 8A
M)#(S94BEG:ELH-$BDK;=8CP6N9@3,57%?A5\%<_4>_C"9S4W^Y9(M/I@I-H6
MWQOJ_FBD0A;WV4A>"-)*D)5">C32H W#LQ%;+\43U^I(_WZA[!1-?\N..O,_
M4$L#!!0    ( -V#8U:82,C1Z00   XN   5    <'-T=BTR,#(S,#,P,U]P
M<F4N>&ULU9I;;^(X%,??1YKOX,V^[$H3PJ6=G:+2$4O;$5IZ$3![>QF9Y #6
M.G9D.P6^_=@![Q!(.J0SNXI;B8#C<_P_Y^<XL>/+]^N8HB<0DG#6\UJ-IH>
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M     &0T-#DT,S1D.&LN:'1M4$L! A0#%     @ W8-C5J47:20''0  >WX
M !$              ( !V!,  &0T-#DT,S1D97@Q,#$N:'1M4$L! A0#%
M  @ W8-C5K<&AY,3#@  _#,  !               ( !#C$  &0T-#DT,S1D
M97@S,2YH=&U02P$"% ,4    " #=@V-6C'21!D,#  !C"P  $0
M    @ %//P  <'-T=BTR,#(S,#,P,RYX<V102P$"% ,4    " #=@V-6VV*]
M*+,&  "E20  %0              @ '!0@  <'-T=BTR,#(S,#,P,U]L86(N
M>&UL4$L! A0#%     @ W8-C5IA(R-'I!   #BX  !4              ( !
MITD  '!S='8M,C R,S S,#-?<')E+GAM;%!+!08     !@ & 'X!  ##3@
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
